Association between atopic dermatitis and dermatophytosis: A TriNetX retrospective cohort study - 18/12/25
Doi : 10.1016/j.jaad.2025.09.073
Maggie H. Zhou, BS a, Jeremy A.W. Gold, MD b, Roderick J. Hay, DM c, Shari R. Lipner, MD, PhD d, ⁎ 
a Columbia University Vagelos College of Physicians and Surgeons, New York, New York
b Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
c St. John's Institute of Dermatology, King's College London, London, UK
d Department of Dermatology, Weill Cornell Medicine, New York
∗ Correspondence to: Shari R. Lipner, MD, PhD, Department of Dermatology, Weill Cornell Medicine, 1305 York Ave 9th Floor, New York, NY 10021 1305 York Ave 9th Floor New York NY 10021
Key words : atopic dermatitis, dermatophytosis, tinea barbae, tinea capitis, tinea corporis, tinea cruris, tinea imbricata, tinea manuum, tinea pedis, tinea unguium, TriNetX
Plan
| Funding sources: None. |
|
| Patient consent: This retrospective study is exempt from informed consent. |
|
| IRB approval status: The data reviewed are a secondary analysis of existing data, do not involve intervention or interaction with human subjects, and are deidentified per the deidentification standard defined in Section §164.514(a) of the HIPAA Privacy Rule. The process by which the data are deidentified is attested through a formal determination by a qualified expert as defined in Section §164.514(b) (1) of the HIPAA Privacy Rule. This formal determination by a qualified expert was refreshed in December 2020. This activity was reviewed by CDC, deemed research not involving human subjects, and was conducted consistent with applicable federal law and CDC policy (see eg, 45 C.F.R. part 46; 21 C.F.R. part 56; 42 U.S.C. §241(d), 5 U.S.C. §552a, 44 U.S.C. §3501 et seq.). |
|
| The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. |
© 2025
American Academy of Dermatology, Inc. Tous droits réservés.
Vol 94 - N° 1
P. 361-363 - janvier 2026 Retour au numéro
Article précédent
- The efficacy and tolerability of off-label dupilumab in acantholytic dyskeratotic disorders
- Megha Udupa, Bianca Te, Valerie C. Doyon, Touraj Khosravi-Hafshejani
- A pilot study of CO2 laser-assisted drug delivery of hyaluronidase for the treatment of scleroderma-induced microstomia
- Bianca E. Ituarte, Priscilla M. Rosa-Nieves, Makayla Schissel, Ashley Wysong, Sarah L. Lonowski
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?